Glenmede Trust Co. NA Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Glenmede Trust Co. NA grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 6.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,605 shares of the biotechnology company's stock after buying an additional 4,145 shares during the period. Glenmede Trust Co. NA owned approximately 0.15% of United Therapeutics worth $24,585,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. LSV Asset Management raised its holdings in shares of United Therapeutics by 82.5% during the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company's stock valued at $307,837,000 after buying an additional 436,851 shares in the last quarter. Swedbank AB purchased a new position in shares of United Therapeutics during the first quarter worth approximately $97,316,000. FMR LLC lifted its holdings in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after acquiring an additional 314,004 shares during the last quarter. Assetmark Inc. boosted its stake in shares of United Therapeutics by 56.9% in the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company's stock valued at $150,492,000 after purchasing an additional 152,249 shares in the last quarter. Finally, Pacer Advisors Inc. grew its holdings in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company's stock valued at $178,972,000 after purchasing an additional 92,240 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $960,576.75. This represents a 79.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of United Therapeutics stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at $13,485,785.60. The trade was a 17.34 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 127,227 shares of company stock worth $47,398,820. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $1.13 during midday trading on Thursday, hitting $378.13. 323,202 shares of the company traded hands, compared to its average volume of 457,791. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The firm has a market cap of $16.88 billion, a P/E ratio of 16.61, a P/E/G ratio of 1.07 and a beta of 0.56. The stock has a 50-day moving average price of $366.89 and a 200 day moving average price of $334.15.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.38 EPS. As a group, equities analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on UTHR. Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Bank of America dropped their target price on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a report on Thursday, August 1st. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research report on Friday, November 1st. Finally, LADENBURG THALM/SH SH raised their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.